Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Smith & Nephew plc (SNNUF)
Watford, GB
Smith & Nephew plc is a global medical technology enterprise dedicated to the development, manufacturing, and worldwide commercialization of an extensive array of medical devices. Its product portfolio spans several key areas. In orthopedics, the company provides knee implants for replacement procedures, hip implants for joint reconstruction, and trauma and extremities products, including both internal and external fixation devices, crucial for stabilizing severe fractures and correcting deformities. For sports medicine, Smith & Nephew offers joint repair solutions tailored for surgeons. This includes specialized instruments, advanced technologies, and implants essential for minimally invasive joint surgeries, targeting soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, the firm supplies arthroscopic enabling technologies that enhance surgical visualization and intervention within joints. This suite encompasses fluid management equipment for surgical access, high-definition cameras, digital imaging capture systems, scopes, light sources, and monitors. It also features radiofrequency, electromechanical, and mechanical tissue resection devices, alongside hand instruments for precise tissue removal. The company also provides dedicated ear, nose, and throat (ENT) solutions. Its Advanced Wound Management division delivers comprehensive solutions for the treatment and prevention of acute and chronic wounds, covering conditions like leg, diabetic, and pressure ulcers, burns, and post-operative wounds. This segment includes advanced wound bioactives, comprising biologics and other bioactive technologies for debridement, dermal repair, and regeneration. Regenerative medicine products, such as skin, bone graft, and articular cartilage substitutes, are also offered. Furthermore, Smith & Nephew provides advanced wound devices, including traditional and single-use negative pressure wound therapy systems, and hydrosurgery technology. Primarily serving healthcare providers globally, Smith & Nephew plc was founded in 1856 and is headquartered in Watford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -4.12% | -18.97% | -6.81% | -9.64% | +4.93% | +0.47% | -31.29% | -11.25% | +150.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+8.5% Q4'25: +18.7% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+55.3% ★ Q4'25: +263.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+15.6% ★ Q4'25: +18.4% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+16.3% ★ Q4'25: +17.9% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+10.2% ★ Q4'25: +23.5% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-0.4% ★ Q4'25: -0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.07× Q4'25: 0.92× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 4 EPS Ana. |
Dec 2027 17 Rev. Ana. 4 EPS Ana. |
Dec 2028 9 Rev. Ana. 5 EPS Ana. |
Dec 2029 14 Rev. Ana. 4 EPS Ana. |
Dec 2030 8 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.63B
est: 4.62B (+0.3%)
|
4.67B
est: 4.69B (-0.5%)
|
4.77B
est: 4.78B (-0.4%)
|
4.90B
est: 4.91B (-0.2%)
|
5.14B
est: 5.12B (+0.4%)
|
4.56B
est: 4.61B (-1.2%)
|
5.21B
est: 5.22B (-0.1%)
|
5.22B
est: 5.20B (+0.3%)
|
5.55B
est: 5.55B (+0.0%)
|
5.81B
est: 5.78B (+0.6%)
|
6.30B
est: 6.14B (+2.7%)
|
6.58B
6.53B – 6.64B
+7.2% YoY
|
6.96B
6.80B – 7.05B
+5.7% YoY
|
7.35B
7.23B – 7.43B
+5.6% YoY
|
7.77B
7.65B – 7.86B
+5.8% YoY
|
8.30B
8.17B – 8.39B
+6.8% YoY
|
| EBITDA |
1.12B
est: 928.20M (+20.1%)
|
1.40B
est: 942.83M (+48.8%)
|
1.43B
est: 961.16M (+49.2%)
|
1.29B
est: 987.33M (+30.4%)
|
1.33B
est: 1.03B (+29.6%)
|
927.00M
est: 927.40M (0.0%)
|
1.20B
est: 1.05B (+14.3%)
|
985.76M
est: 1.05B (-5.7%)
|
956.00M
est: 1.11B (-14.2%)
|
1.22B
est: 1.22B (0.0%)
|
1.61B
est: 1.30B (+24.2%)
|
1.39B
1.38B – 1.40B
+7.2% YoY
|
1.47B
1.44B – 1.49B
+5.7% YoY
|
1.55B
1.53B – 1.57B
+5.6% YoY
|
1.64B
1.62B – 1.66B
+5.8% YoY
|
1.75B
1.73B – 1.77B
+6.8% YoY
|
| EBIT |
622.00M
est: 458.78M (+35.6%)
|
1.02B
est: 466.01M (+119.5%)
|
976.89M
est: 475.07M (+105.6%)
|
852.00M
est: 488.00M (+74.6%)
|
818.00M
est: 508.55M (+60.8%)
|
433.00M
est: 458.38M (-5.5%)
|
645.77M
est: 518.35M (+24.6%)
|
447.71M
est: 516.51M (-13.3%)
|
429.00M
est: 550.93M (-22.1%)
|
666.00M
est: 651.94M (+2.2%)
|
1.03B
est: 692.69M (+48.0%)
|
742.86M
736.74M – 749.51M
+7.2% YoY
|
785.49M
767.84M – 795.86M
+5.7% YoY
|
829.32M
816.42M – 838.55M
+5.6% YoY
|
877.33M
863.69M – 887.10M
+5.8% YoY
|
936.77M
922.21M – 947.20M
+6.8% YoY
|
| Net Income |
410.00M
est: 710.88M (-42.3%)
|
784.00M
est: 715.89M (+9.5%)
|
767.00M
est: 767.64M (-0.1%)
|
663.00M
est: 836.54M (-20.7%)
|
600.00M
est: 886.80M (-32.3%)
|
448.00M
est: 551.40M (-18.8%)
|
524.00M
est: 724.30M (-27.7%)
|
223.00M
est: 680.93M (-67.3%)
|
263.00M
est: 720.41M (-63.5%)
|
412.00M
est: 725.85M (-43.2%)
|
638.90M
est: 866.73M (-26.3%)
|
958.37M
939.00M – 972.24M
+10.6% YoY
|
1.07B
1.05B – 1.09B
+11.9% YoY
|
1.19B
1.16B – 1.20B
+10.7% YoY
|
1.25B
1.23B – 1.27B
+5.6% YoY
|
1.33B
1.31B – 1.35B
+6.3% YoY
|
| SGA |
2.64B
est: 2.23B (+18.5%)
|
2.03B
est: 2.26B (-10.5%)
|
2.15B
est: 2.31B (-6.8%)
|
2.19B
est: 2.37B (-7.8%)
|
2.31B
est: 2.47B (-6.4%)
|
2.56B
est: 2.23B (+15.0%)
|
2.39B
est: 2.52B (-5.0%)
|
2.44B
est: 2.51B (-3.0%)
|
2.60B
est: 2.68B (-2.8%)
|
2.65B
est: 2.68B (-1.1%)
|
2.96B
est: 2.85B (+3.8%)
|
3.05B
3.03B – 3.08B
+7.2% YoY
|
3.23B
3.16B – 3.27B
+5.7% YoY
|
3.41B
3.36B – 3.45B
+5.6% YoY
|
3.61B
3.55B – 3.65B
+5.8% YoY
|
3.85B
3.79B – 3.90B
+6.8% YoY
|
| EPS |
0.46
est: 0.81 (-43.3%)
|
0.88
est: 0.82 (+7.7%)
|
0.88
est: 0.88 (+0.4%)
|
0.76
est: 0.95 (-20.4%)
|
0.71
est: 1.01 (-29.9%)
|
0.51
est: 0.63 (-19.0%)
|
0.59
est: 0.83 (-28.6%)
|
0.26
est: 0.78 (-66.6%)
|
0.30
est: 0.82 (-63.5%)
|
0.47
est: 0.83 (-43.5%)
|
0.74
est: 0.99 (-25.5%)
|
1.10
1.08 – 1.11
+10.6% YoY
|
1.23
1.20 – 1.25
+11.9% YoY
|
1.36
1.33 – 1.38
+10.7% YoY
|
1.44
1.41 – 1.46
+5.6% YoY
|
1.53
1.50 – 1.55
+6.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STMicroelectronics Holding II B.V. (“ST Holding II”) | 250.70M | 27.50% | 58.77M | — | 64.10M | — | HC | Delaware | 2018-01-30 | ↗ |
| 2 | Cevian Capital II GP Limited | 44.67M | 5.11% | 44.67M | — | 44.67M | 10.00 | IA, OO | Jersey | 2024-07-09 | ↗ |
| 3 | Wellington Management Company LLP | 43.77M | 5.00% | — | 27.89M | — | — | IA | Delaware | 2019-02-12 | ↗ |
| 4 | Wellington Group Holdings LLP | 42.67M | 4.87% | — | 34.53M | — | — | HC | Massachusetts | 2021-02-03 | ↗ |
| 5 | Wellington Investment Advisors Holdings LLP | 42.67M | 4.87% | — | 34.53M | — | — | HC | Massachusetts | 2021-02-03 | ↗ |
| 6 | Wellington Management Group LLP | 42.67M | 4.87% | — | 34.53M | — | — | HC | Massachusetts | 2021-02-03 | ↗ |
| 7 | First Trust Portfolios L.P., First Trust Advisors L.P., The Charger Corporation | 1.87M | 24.96% | 50.31M | — | 54.92M | — | BD, IA, HC | Delaware | 2017-01-27 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deepak S. Nath | Chief Executive Officer & Director | 5M | — |
| John Terence Rogers | Chief Financial Officer & Executive Director | 3M | male |
| Charles Reynolds | Head of Corporate Communication | — | male |
| Elga Lohler | Chief Human Resources Officer | — | female |
| Emily Heaven | Head of Investor Relations | — | — |
| Helen Barraclough | Group General Counsel & Company Secretary | — | female |
| Paul Connolly | President of Global Operations | — | male |
| Ajay Dhankhar | Chief Corporate Development & Strategy Officer | — | male |
| Vasant Padmanabhan | President Research & Development, ENT and Emerging Markets | — | — |
| Alison Parkes | Chief Compliance Officer & Compliance APAC | — | female |
No Senate trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNNUF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
